Abbott and Dexcom have resolved all patent disputes related to continuous glucose monitoring products through a mutual agreement. The settlement involves the dismissal of pending cases in courts and patent offices worldwide and includes a commitment not to litigate patent, trade dress, and design rights disputes against each other for the next decade. Notably, the agreement does not involve any financial compensation between the parties. The settlement also includes global, non-exclusive licenses for certain patents related to analyte sensing but does not entail royalties or additional payments.
Abbott views the agreement as a positive step, allowing the company to concentrate on advancing its technologies and supporting individuals with diabetes. This settlement follows a 2014 agreement between the two companies, which included a cross-licensing deal. Since the expiration of that agreement in 2021, both companies have filed multiple patent lawsuits, including one in March 2024, where a jury found that Dexcom’s G6 monitors infringed on Abbott’s patents. The agreement represents a strategic decision by both companies to avoid prolonged legal conflicts and direct their resources toward improving patient outcomes in diabetes management.
